SCHEMBL418081

SCHEMBL418081

Cc1ccc(-c2nc(I)c(C(=O)O)o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.49
GAA P10253 4/20 0.47
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 5/20 0.44
TARBP2 Q15633 1/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 6/20 0.44
NPC1 O15118 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
HPGD P15428 4/20 0.43
HSD17B10 Q99714 2/20 0.43
PKM P14618 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31301354 0.85 GAA (0.58) IKBKBGAAKDM4EALDH1A1TARBP2
SCHEMBL416912 0.82 TARBP2 (0.64) IKBKBKDM4EALDH1A1TARBP2LMNA
SCHEMBL10104609 0.75 GAA (0.51) IKBKBGAAKDM4EALDH1A1TARBP2
SCHEMBL11623745 0.73 KDM4E (0.61) IKBKBGAAKDM4EALDH1A1TARBP2
SCHEMBL2789941 0.73 GAA (0.73) IKBKBGAAKDM4EALDH1A1TARBP2
Hydrochloric Acid SCHEMBL11621803 0.72 TARBP2 (0.64) IKBKBGAAKDM4EALDH1A1TARBP2
SCHEMBL779982 0.72 KDM4E (0.73) IKBKBGAAKDM4EALDH1A1TARBP2
Hydrochloric Acid SCHEMBL11623044 0.71 GAA (0.71) IKBKBGAAKDM4EALDH1A1TARBP2
SCHEMBL22658076 0.70 ALDH1A1 (0.57) IKBKBGAAKDM4EALDH1A1TARBP2
SCHEMBL3128951 0.69 IKBKB (0.54) IKBKBGAAKDM4EALDH1A1TARBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2410858-B1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2016-09-07 EP disclosed
US-8946231-B2 P2X3, receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2015-02-03 US disclosed
EP-2410858-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
US-20120021074-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2012-01-26 US disclosed
WO-2010111059-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120021074-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 IKBKB 1174/4885GAA 4588/4885KDM4E 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.